Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Inhibrx Biosciences Reports 62.7% Response Rate in Ewing Sarcoma Trial for Ozekibart

Inhibrx Biosciences announced updated Phase 1/2 clinical data showing that ozekibart, in combination with standard chemotherapy, achieved a 62.7% overall response rate in relapsed or refractory Ewing sarcoma. The results represent a significant improvement over historical benchmarks, which typically yield response rates between 15% and 30%.

Vaccine, coronavirus, medical, hand. Stock photo illustrating Inhibrx Biosciences' other story.
Inhibrx Biosciences, Inc. · Healthcare · Photo: spencerbdavis1 / Pixabay

Key highlights

  • Overall response rate of 62.7% achieved among 51 response-evaluable patients
  • Disease control rate reached 86.3% in a heavily pretreated patient population
  • Median progression-free survival recorded at 6.0 months versus 3-4 months historically
  • Two patients achieved complete responses and 30 patients showed partial responses
  • Acceptable safety profile maintained with no evidence of unexpected hepatotoxicity

Clinical Trial Outcomes and Efficacy

Inhibrx Biosciences shared updated Phase 1/2 expansion study results for ozekibart (INBRX-109), a tetravalent death receptor 5 agonist. The study evaluated the candidate in combination with irinotecan and temozolomide for patients with relapsed or refractory Ewing sarcoma. As of the September 2026 data cutoff, 60 patients were treated, including nine adolescents. The combination showed significant efficacy, with 84.3% of evaluable patients experiencing a measurable reduction in tumor size. Notably, two patients achieved complete responses, and one patient has maintained a partial response for over two years, suggesting clinical durability in an aggressive disease setting.

Market Benchmarks and Regulatory Path

These clinical outcomes represent a substantial improvement over historical benchmarks for Ewing sarcoma treatment. Current standard regimens typically yield an overall response rate between 15% and 30%, whereas ozekibart reached 62.7%. The extension of median progression-free survival to 6.0 months from the historical average of 3 to 4 months highlights the potential for improved patient outcomes. Inhibrx intendeds to discuss these results with the FDA to advance the program. The agency has already accepted a biologics license application for ozekibart in conventional chondrosarcoma, indicating a broadening regulatory profile for the therapeutic candidate.

Strategic Commentary

“In relapsed or refractory Ewing sarcoma, achieving a 62.7% overall response rate, an 86.3% disease control rate, and clinically meaningful durability is particularly compelling in a population that has exhausted effective options.”

Mark Lappe, Chief Executive Officer, Inhibrx Biosciences

Business and Financial Profile

Inhibrx Biosciences is a clinical-stage biopharmaceutical firm utilizing a proprietary modular protein engineering platform to develop therapeutics for oncology and orphan diseases. Despite the positive clinical update, INBX shares have experienced a 18.13% decline over the past week, leaving the stock with a 14-day RSI of 38.2. The company maintains a market capitalization of approximately $1.1 billion. While quarterly revenue stands at $2.0 million, the focus remains on R&D investment. Moving ozekibart toward potential commercialization in the underserved Ewing sarcoma market, which affects roughly 2,500 individuals in the U.S., remains a central strategic objective.

Management commentary

“The updated clinical data to be presented at CTOS underscore the deep activity and expanding reach of ozekibart in aggressive, difficult-to-treat bone and soft tissue sarcomas.”

Mark Lappe, Chief Executive Officer of Inhibrx
Inhibrx Biosciences, Inc. · financial snapshot
Share price$74.18
Market cap$1.1B
Revenue (annual)$1M
1-month price change-17.42%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Inhibrx Biosciences announcing updated Phase 1/2 clinical data for ozekibart in Ewing sarcoma.

Read the filing ↗

Track Inhibrx Biosciences, Inc. live

Get the next Inhibrx Biosciences, Inc. SEC filing seconds after it lands.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.